Bioxodes
Bioxodes is a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of therapeutics for patients with thrombo-inflammatory diseases. We leverage our deep understanding of the thrombotic and inflammatory processes to design novel product candidates with an aim to address unmet medical needs.
Bioxodes
Bioxodes is a clinical-stage biopharmaceutical company developing a first-in-class drug, BIOX-101 (Ir-CPI), to prevent thrombosis and neuroinflammation in hemorrhagic stroke patients.
About
Needs Assessment
Active buying signals and potential business opportunities
Technology Requirements
Technologies for assessing cerebral lesion and hemorrhage volumes (MRI).
Histological evaluation of neutrophil infiltration and neuronal degeneration.
Service Requirements
Clinical trial management
Regulatory consulting
Clinical data management
Medical writing
IP Management
Medical affairs support
Strategic advice for market access
Infrastructure Requirements
Facilities for conducting preclinical and clinical studies.
Manufacturing and distribution capabilities for Ir-CPI and BIOX-101.
Ramping up production for potential registrational Phase 2b trial.
AI Insights
Growth Trajectory
Bioxodes shows promising growth potential as they advance BIOX-101 through clinical trials and explore its application to other thrombo-inflammatory diseases, signaling a focus on market expansion and innovation.
Market Opportunity
Bioxodes has a significant market opportunity in addressing the unmet need for effective treatments for ICH by achieving anticoagulation without increasing hemorrhagic risk, giving them a competitive edge as a first-in-class drug candidate.
Access Our Live VC Funding Database
30,000+ funded startups
tracked in the last 3 months
B2B verified emails
of key decision makers
Growth metrics
Real-time company performance data
Live updates
of new VC funding rounds
Advanced filters
for sophisticated queries
API access
with multiple export formats